Cost-effectiveness study of ceftriaxone and cefotaxime for the treatment of community acquired pneumonia;Estudio de costo-efectividad de ceftriaxona y cefotaxima en el tratamiento de neumonia adquirida en la comunidad

Revista de Investigacion Clinica

Volumn 52, Issue 4, 2000, Pages 418-426

  García Contreras, Fernando ^a,c   Del Angel García, Guadalupe ^b   Ramírez Cuenca, Abelardo ^a   Malváez Valdes, Miguel ^a   Vega Yáñez, Alfonso ^a   Amato, Dante ^b  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b HOSPITAL DE ESPECIALIDADES   (Mexico)

^c CSPI Coahuila   (Mexico)

Author keywords

Cefotaxime; Ceftriaxone; Community acquired pneumonia; Cost effectiveness

Indexed keywords

AMPICILLIN; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; ERYTHROMYCIN; PENICILLIN G;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PNEUMONIA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORINS; COMMUNITY-ACQUIRED INFECTIONS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; SENSITIVITY AND SPECIFICITY;

EID: 1642618008     PISSN: 00348376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Rhew DC, Riedinger MS, Sandhu M, Bowers C, Greengold N, Weingarten SR. A Prospective, Multicenter Study of a Pneumonia Practice Guideline. Chest 1998; 114: 115-9.
2. Lim TK. Emerging pathogens for pneumonia in Singapore. Ann Acad Med Singapore 1997; 26 : 651-8.
3. Davis R, Bryson MH. Ceftriaxona Evaluación farmacoeconómica de su aplicación en el tratamiento de las infecciones serias. Pharmacoeconomics 1994; 6: 249-69.
4. Bariffi F, Sanduzzi A, Pontiaccello A. Epidemiology of lower respiratory tract infections. J Chemother 1995; 7: 263-76.
5. Porath A, Schlaeffer F, Lieberman D. Appropriateness of hospitalization of patients with community acquired pneumonia. Ann Emerg Med 1996; 21: 176-83.
6. Michetti G, Pugliese C, Mabmerga M, Ori-belometti M, Villa R, Ranzanici S et al. Is there difference in etiology between hospitalized and outpatients? Minerva Med 1995; 86: 341-51.
7. Cosentini R, Blasi F. New pathogens for respiratory infections. Curr Opin Pulm Med 1996; 2: 174-80.
8. Ginesu F, Pirina P, Deiola G, Mele S, Fois G. Etiology and therapy of community-acquired pneumonia. J Chemother 1997; 9: 285-92.
9. File TM, Tan JS. Incidence, etiologic pathogens, and diagnostic testing of community-acquired pneumoniae. Curr Opin Pulm Med 1997; 3: 89-97.
10. Brown R. Ceftriaxone in treatment of serious infections. Pneumonia and lower respiratory tract infections. Chemotherapy 1991; 37(Suppl 3): 11-4.
11. Ortqvist A. Antibiotic treatment of community-acquired pneumoniae in clinical practice: A European perspective. J Antimicrob Chemother 1995; 35: 205-12.
12. Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995; 333: 1618-24.
13. Cleeland R, Squires E. Antimicrobial activity of ceftriaxone : a review. Am J Med 1984; 77: 3-11.
14. Schwarzmann SW. Novel cost-effective approaches to the treatment of community-acquired infections. Ann Pharmacother 1998; 32: S27-30.
15. Mandell LA. Ceftriaxone compared with cefotaxime for serious bacterial infections. J Infect Dis 1989; 160: 443-7.
16. American Thoracic Society. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993;148: 1418-26.
17. Ericsson HM, Sherris JC. Antibiotic sensitivity testing; report of an international collaborative study. Acta Pathol Microbiol Scand. B Microbiol 1971; suppl 217: 1-90.
18. Drummond M, Stoddart G, Torrance G. Methods for the economic evaluation of health care programmes. Great Britain: Oxford University Press, 1987: 30.
19. Greenhalgh T. How to read a paper. Papers that tell you what things cost (economic analyses). BMJ 1997; 315: 596-9.
20. Lieberman D, Schlaeffer F, Boldur I, Lieberman D, Horowitz S, Friedman MG et al. Multiple pathogens in adult patients admitted with community-acquired pneumonia: one year prospective study of 346 consecutive patients. Thorax 1996; 51: 179-84.
21. Yeo SF, Akalin E, Arikan S, Auckenthaler R, Bergan T, Dornbusch K et al. Susceptibility testing of Haemophilus influenzae an international collaborative study in quality assessment. J Antimicrob Chemother 1996; 38: 363-86.
22. Cano SB, Fujita NK. Formulary evaluation of third-generation cephalosporins: using decision analysis. Am J Hosp Pharm 1988; 45: 566-9.
23. Barriere SL, Flaherty JF, Third-generation cephalosporins: a critical evaluation. Am J Hasp Pharm 1984; 3: 351-73.
24. Dansey RD, Jacka PJ, Strachan SA, Hay M. Comparison of cefotaxime with ceftriaxone given intramuscularly 12-hourly for community-acquired pneumonia. Diagn Microbiol Infect Dis 1992; 15: 81-4.
25. Rascio N, Marseglia GL, Ugazio AG. The treatment of pneumonia in children: ceftriaxone (Rocephin) vs. Amoxicillin plus tobramycin: an open trial. Clin Trials J 1985;22:401-4.
26. Bittner MJ, Pugsley MP, Horowitz EA, Strike DG, Sanders CC, Preheim LC, Randomized comparison of ceftriaxone and cefomandole therapy in lower respiratory tract infections in elderly population. J Antimicrob Chemoter 1986; 18: 621-7.
27. Gladen HE, Evaluating the cost-effectiveness of treatment with third-generation cephalosporins. Diagn Microbiol Infect Dis 1992; 15: 99-105.
28. Foran RM, Brett JL, Wulf PH. Evaluating the cost impact of intravenous antibiotic dosing frequencies. Drug Intell Clin Pharm 1991; 25: 546-51.
29. Crane VS. Projected cost savings associated with cefmetazole. A new cephamycin for the hospitalized patient. Hosp form 1991; 26: 302-10.
30. a: 387-92.
31. Cousisns DH, LeeM, Stanaway M et al. Implementation and evaluation of a centralized IV additive service for antibiotic injections. Pharm J 1989; Suppl 242.: HS14-6.
32. Meyer RD, Risk factors and comparisons of clinical nephrotoxicity of aminoglycosides. Am JMed 1986; 80 Suppl. 6B:119.
33. Gatell JM, Ferran F, Araujo V et al. Univariate and multivariate analyses of risk factors predisposing to auditory toxicity in patients receiving aminoglycosides. Antimicrob Agents Chemoter 1987; 31: 1383.
34. Mathews A, Bailie GR, Clinical pharmacokinetics, toxicity and cost effectiveness analysis of aminoglycosides and aminoglycoside dosing services. J Clin Pharm Ther 1987; 12: 273-91.
35. Eisenberg JM, Koffer H, Glick HA et al. What is the cost of nephrotoxicity associated with aminoglycosides?. Ann Intern Med 1987; 107: 900-9.